^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GNR-051

    i
    Other names: GNR-051
    Associations

    News

    Trials
    Company:
    Generium
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, AO GENERIUM | Trial completion date: Jun 2024 --> Jan 2025
    Trial completion date • Metastases
    |
    GNR-051
    1year
    A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, AO GENERIUM | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Nov 2022
    Enrollment closed • Trial primary completion date • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    GNR-051
    over2years
    A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=48, Recruiting, AO GENERIUM | Trial completion date: Nov 2024 --> Jun 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-1 (Programmed cell death 1)
    |
    GNR-051